Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Other Operating Expenses (2019 - 2025)

BridgeBio Pharma's Other Operating Expenses history spans 6 years, with the latest figure at $7.9 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 278.02% year-over-year to $7.9 million; the TTM value through Dec 2025 reached $21.0 million, up 440.54%, while the annual FY2025 figure was $21.0 million, 440.54% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $7.9 million at BridgeBio Pharma, up from $6.6 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $7.9 million in Q4 2025 and bottomed at -$2.2 million in Q3 2024.
  • The 5-year median for Other Operating Expenses is $1.1 million (2024), against an average of $1.8 million.
  • The largest annual shift saw Other Operating Expenses soared 542.2% in 2022 before it plummeted 463.88% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $1.6 million in 2021, then plummeted by 58.28% to $647000.0 in 2022, then fell by 7.57% to $598000.0 in 2023, then surged by 248.49% to $2.1 million in 2024, then surged by 278.02% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Other Operating Expenses are $7.9 million (Q4 2025), $6.6 million (Q3 2025), and $3.7 million (Q2 2025).